EI-001
Phase 2Small molecule
EI-001 is one of 36 small molecule programs targeting Vitiligo. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
103 competitors in Vitiligo
#DrugCompanyPhaseTrials
1Rinvoq
AbbViePhase 3
Opzelura
PfizerPhase 3
Prograf
VVeloxis Pharmaceuticals
Phase 3
Povorcitinib
IncytePhase 3
Olumiant
Eli LillyPhase 2
Otezla
AmgenPhase 2
Scenesse
CClinuvel Pharmaceuticals Limited
Phase 2
Kenalog
BBassett Healthcare
Phase 2
Glucophage
Boehringer IngelheimPhase 2
Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EI-001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details